topotecan has been researched along with suramin in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (50.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Cassidy, J; Graham, MA; Jodrell, D; Kaye, SB; Workman, P | 1 |
| Kaufmann, SH; Rowinsky, EK | 1 |
| Armand, JP | 1 |
| Bajorin, DF; Bosl, GJ; Carousso, M; Feldman, DR; Ginsberg, MS; Motzer, RJ; Patil, S; Sheinfeld, J; Trinos, MJ | 1 |
3 review(s) available for topotecan and suramin
| Article | Year |
|---|---|
Pharmacokinetics and early clinical studies of selected new drugs.
Topics: Animals; Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Agents; Aziridines; Camptothecin; Clinical Trials, Phase I as Topic; Humans; Indolequinones; Indoles; Irinotecan; Lactones; Macrolides; Neoplasms; Suramin; Topotecan | 1993 |
Topotecan in combination chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Humans; Paclitaxel; Suramin; Topoisomerase I Inhibitors; Topotecan | 1997 |
New anticancer drugs in Europe.
Topics: Antineoplastic Agents; Apoptosis; Europe; Humans; Signal Transduction; Suramin; Topotecan | 1997 |
3 other study(ies) available for topotecan and suramin
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Progression-free and overall survival in patients with relapsed/refractory germ cell tumors treated with single-agent chemotherapy: endpoints for clinical trial design.
Topics: Adolescent; Adult; Antineoplastic Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease-Free Survival; Drug Resistance, Neoplasm; Endpoint Determination; Female; Humans; Indoles; Kaplan-Meier Estimate; Male; Mediastinal Neoplasms; Middle Aged; Neoplasms, Germ Cell and Embryonal; Pyrroles; Retroperitoneal Neoplasms; Retrospective Studies; Sunitinib; Suramin; Testicular Neoplasms; Topotecan; Treatment Outcome; Young Adult | 2012 |